The study will aim to compare ANX-530, a generic anti-cancer drug, to Navelbine, already approved for small cell cancers. The new study is to be initiated in 2007, and the company expects to file a New Drug Application [NDA] by the end of 2007.
Preclinical studies of ANX-530 have shown the following conclusions:
- Pharmacokinetics were unchanged between ANX-530 and Navelbine
- No difference in anti-tumor activity was found between the two formulations
- ANX-530 showed less irritation of the vein and site of injection
Shares of ADVENTRX were trading at $2.75 a share, up more than 4% in pre-market action.
ANX 1-yr chart